Epic Sciences

Press Releases

05.05.2014

Epic Sciences selected to present at Cavendish Global Health Impact Forum.

Epic Sciences, developer of novel diagnostics to personalize and advance the treatment and management of cancer, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 New York, NY. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences.

04.08.2014

Epic sciences appoints Pascal Bamford, Ph.D., as vice president of product development.

Epic Sciences announced today the appointment of Pascal Bamford, Ph.D. as vice president of product development. Dr. Bamford has more than 15 years of experience in developing complex, automated diagnostic systems for digital pathology. Prior to joining Epic Sciences, Dr. Bamford served as senior project leader for Advanced Staining Assays at Ventana Medical Systems, Inc., a member of the Roche Group. Dr. Bamford is recognized as a creative innovator and project leader with a successful track record of translating new technologies into high-impact products.

01.29.2014

Epic Sciences partners with LabCorp to accelerate European clinical sample processing CTC technology.

Epic Sciences announced today an agreement with Laboratory Corporation of America® Holdings (LabCorp) to expedite sample processing for Epic's circulating tumor cell (CTC) technology to support European clinical trials.

01.29.2014

Epic Sciences and collaborators to present six novel abstracts at ASCO GU addressing the clinical applicability of Epic's CTC technology in prostate cancer.

Epic Sciences, in collaboration with the company's academic and pharmaceutical partners including Memorial Sloan Kettering Cancer Center, Institute of Cancer Research, Weill Cornell Medical College, University of Michigan, and Progenics Pharmaceuticals, will present six novel abstracts at the American Society of Clinical Oncology Genitourinary (ASCO GU) conference, taking place January 30 to February 1 in San Francisco.

02.12.2013

Epic Sciences' research in prostate cancer presented at the 2013 ASCO Genitourinary Cancers Symposium.

Epic Sciences, a private biotech company that develops breakthrough cancer diagnostics, announced the presentation of a research poster at the 2013 Genitourinary Cancers Symposium taking place February 14 to 16 in Orlando, Fla. The symposium presents the latest research in genitourinary cancers and is sponsored by three leading medical specialty societies: American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO).

01.24.2013

Epic Sciences awarded a phase II SBIR contract from NCI/NIH to develop a lung cancer diagnostic blood test.

Epic Sciences, a private biotech company that develops breakthrough cancer diagnostics, announced receipt of a Phase II contract from the Small Business Innovation Research (SBIR) program supported by the National Cancer Institute (NCI) and the National Institutes of Health (NIH). The contract will fund the further development of an assay to identify and characterize circulating tumor cells (CTCs) in lung cancer patients. The results of this contract are expected to provide a basis for the development of new cancer diagnostic products.

08.15.2012

Epic Sciences announces six pharma circulating tumor cell collaborations.

Epic Sciences, a privately held cancer diagnostics company, announced today that it has established collaborations with six pharmaceutical partners employing Epic's proprietary Circulating Tumor Cell ("CTC") technology. The partners include two of the top four pharmaceutical companies worldwide. In total, the collaborations include 12 clinical trials involving over 40 distinct projects measuring 18 different protein or genomic tumor markers on CTCs. The clinical trials include sites in the US, Europe and Asia with over 1500 patients and 2500 clinical samples in prostate, lung, breast, pancreatic and ovarian cancers.